The FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck & Co, ahead of the original drug’s US patent expiry in June.
Mylan and Fujifilm Kyowa Kirin Biologics have got their Humira biosimilar approved in Europe – the fifth cut-price competitor approved ahead of patent expiry on AbbVie’s inflammatory diseas
